PubRank

D C Mash

Author PubWeight™ 81.12‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 1998 2.92
2 Inactivation of human immunodeficiency virus-1 at short time intervals using undiluted bleach. J Acquir Immune Defic Syndr 1993 2.36
3 Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci 1996 1.78
4 Cyanobacterial neurotoxin BMAA in ALS and Alzheimer's disease. Acta Neurol Scand 2009 1.75
5 Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol 1999 1.55
6 Frequency and type of electrocardiographic abnormalities in cocaine abusers (electrocardiogram in cocaine abuse). Am J Cardiol 1994 1.53
7 Loss of high-affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: implications for the failure of cholinergic replacement therapies. Ann Neurol 1991 1.49
8 Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity. J Forensic Sci 1997 1.43
9 Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med 2013 1.31
10 Catechols in post-mortem brain of patients with Parkinson disease. Eur J Neurol 2010 1.30
11 Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 1997 1.27
12 Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Ann Neurol 1997 1.27
13 Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 1985 1.26
14 Detection of HIV-1 DNA in needle/syringes, paraphernalia, and washes from shooting galleries in Miami: a preliminary laboratory report. J Acquir Immune Defic Syndr Hum Retrovirol 1996 1.24
15 High affinity cocaine recognition sites on the dopamine transporter are elevated in fatal cocaine overdose victims. J Pharmacol Exp Ther 1994 1.21
16 Up-regulation of D3 dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities. Brain Res Mol Brain Res 1997 1.19
17 MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy. Neurology 2011 1.19
18 Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp Neurol 1999 1.19
19 Preliminary laboratory studies of inactivation of HIV-1 in needles and syringes containing infected blood using undiluted household bleach. J Acquir Immune Defic Syndr 1994 1.18
20 Psychotic symptoms in Parkinson's disease. From description to etiology. J Neurol 2005 1.14
21 Autoradiographic localization of M1 and M2 muscarine receptors in the rat brain. Neuroscience 1986 1.13
22 Cocaethylene: a unique cocaine metabolite displays high affinity for the dopamine transporter. J Neurochem 1991 1.03
23 Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem 1995 1.01
24 Pharmacokinetics of Hoasca alkaloids in healthy humans. J Ethnopharmacol 1999 0.99
25 Differential cholinergic innervation within functional subdivisions of the human cerebral cortex: a choline acetyltransferase study. J Comp Neurol 1992 0.99
26 Localization of nerve growth factor receptors in cholinergic neurons of the human basal forebrain. Neurosci Lett 1986 0.98
27 Neurofibrillary tangles in cholinergic pedunculopontine neurons in Alzheimer's disease. Ann Neurol 1988 0.97
28 DJ-1 mutations are a rare cause of recessively inherited early onset parkinsonism mediated by loss of protein function. J Med Genet 2004 0.97
29 Dopamine transporter-immunoreactive neurons decrease with age in the human substantia nigra. J Comp Neurol 1999 0.95
30 Response of F344 rats to inhalation of subclinical levels of sarin: exploring potential causes of Gulf War illness. Toxicol Ind Health 2001 0.94
31 Radioligand binding and immunoautoradiographic evidence for a lack of toxicity to dopaminergic nerve terminals in human cocaine overdose victims. Brain Res 1997 0.94
32 Dopamine transporter DAT and receptor DRD2 variants affect risk of lethal cocaine abuse: a gene-gene-environment interaction. Transl Psychiatry 2013 0.94
33 Kappa2 opioid receptors in limbic areas of the human brain are upregulated by cocaine in fatal overdose victims. J Neurosci 1997 0.94
34 Vesicular acetylcholine transporter density and Alzheimer's disease. Neurobiol Aging 1997 0.92
35 Cytosolic proteomic alterations in the nucleus accumbens of cocaine overdose victims. Mol Psychiatry 2006 0.91
36 Dopamine D(1) receptor expression in human basal ganglia and changes in Parkinson's disease. Brain Res Mol Brain Res 2001 0.90
37 Quantitation of N,N-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with ayahuasca. J Anal Toxicol 1996 0.89
38 Characterization of L-[3H]nicotine binding in human cerebral cortex: comparison between Alzheimer's disease and the normal. J Neurochem 1986 0.89
39 Cocaethylene is more potent than cocaine in mediating lethality. Pharmacol Biochem Behav 1991 0.88
40 Localization of nerve growth factor receptors in the normal human brain and in Alzheimer's disease. Neurobiol Aging 1989 0.88
41 Cholinergic projections from the parabigeminal nucleus (Ch8) to the superior colliculus in the mouse: a combined analysis of horseradish peroxidase transport and choline acetyltransferase immunohistochemistry. Brain Res 1986 0.87
42 Effects of post-mortem delay on subunits of ionotropic glutamate receptors in human brain. Brain Res Mol Brain Res 2000 0.87
43 Cholinergic innervation of the amygdaloid complex in the human brain and its alterations in old age and Alzheimer's disease. J Comp Neurol 1993 0.86
44 Somatic sensory projections to the pretectum in the cat. Brain Res 1978 0.86
45 Visualizing dopamine and serotonin transporters in the human brain with the potent cocaine analogue [125I]RTI-55: in vitro binding and autoradiographic characterization. J Neurochem 1994 0.86
46 Characterization of kappa1-opioid receptor binding in human insular cortex. Life Sci 1999 0.85
47 In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats. J Pharmacol Exp Ther 2001 0.85
48 Drug interactions with the dopamine transporter in cryopreserved human caudate. J Pharmacol Exp Ther 2001 0.84
49 Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine. Drug Metab Dispos 1998 0.84
50 Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain. J Neural Transm (Vienna) 2003 0.84
51 Can Alzheimer's type pathology influence the clinical phenotype of Parkinson's disease? Acta Neurol Scand 2005 0.83
52 Spatial memory in aged rats is related to PKCgamma-dependent G-protein coupling of the M1 receptor. Neurobiol Aging 2005 0.83
53 Mapping dopamine transporters in the human brain with novel selective cocaine analog [125I]RTI-121. Synapse 1995 0.83
54 Interactions of cocaine with primary and secondary recognition sites on muscarinic receptors. Mol Pharmacol 1992 0.83
55 Motor fluctuations and dyskinesias in advanced/end stage Parkinson's disease: a study from a population of brain donors. J Neural Transm (Vienna) 2006 0.83
56 Galanin receptor plasticity within the nucleus basalis in early and late Alzheimer's disease: an in vitro autoradiographic analysis. Neuropharmacology 2000 0.82
57 Dementia in Parkinson's disease: a post-mortem study in a population of brain donors. Int J Geriatr Psychiatry 2005 0.81
58 Galanin: neurobiologic mechanisms and therapeutic potential for Alzheimer's disease. CNS Drug Rev 2001 0.81
59 Localization of muscarinic receptor subtypes in brain stem areas regulating sleep. Neuroreport 1994 0.81
60 Distinct kinetic binding properties of N-[3H]-methylscopolamine afford differential labeling and localization of M1, M2, and M3 muscarinic receptor subtypes in primate brain. Synapse 1993 0.81
61 Dopamine transporter mRNA in autopsy studies of chronic cocaine users. Brain Res Mol Brain Res 1999 0.81
62 Differential alterations in muscarinic receptor subtypes in Alzheimer's disease: implications for cholinergic-based therapies. Life Sci 1995 0.81
63 Semi-quantitative reverse-transcriptase polymerase chain reaction: an approach for the measurement of target gene expression in human brain. Brain Res Brain Res Protoc 1999 0.80
64 Adenosine A(2A) receptor mRNA expression in Parkinson's disease. Neurosci Lett 2000 0.80
65 Circadian variations in radioligand binding to muscarine receptors in rat brain dependent upon endogenous agonist occupation. Brain Res 1985 0.80
66 Comparison of the concentration of messenger RNA encoding four muscarinic receptor subtypes in control and Alzheimer brains. Brain Res Mol Brain Res 1992 0.80
67 The serotonin agonist m-chlorophenylpiperazine (mCPP) binds to serotonin transporter sites in human brain. Neuroreport 1995 0.79
68 Comparative neuropharmacology of ibogaine and its O-desmethyl metabolite, noribogaine. Alkaloids Chem Biol 2001 0.79
69 Attenuation of muscarinic receptor-G-protein interaction in Alzheimer disease. Mol Chem Neuropathol 1995 0.79
70 Expression of glutamatergic genes in healthy humans across 16 brain regions; altered expression in the hippocampus after chronic exposure to alcohol or cocaine. Genes Brain Behav 2014 0.78
71 Noribogaine stimulates naloxone-sensitive [35S]GTPgammaS binding. Neuroreport 1998 0.78
72 21-aminosteroids interact with the dopamine transporter to protect against 1-methyl-4-phenylpyridinium-induced neurotoxicity. J Neurochem 1992 0.78
73 Pargyline-sensitive selective accumulation of a radiolabeled MPTP analog in the primate cerebral cortex and basal ganglia. Synapse 1990 0.78
74 Noribogaine (12-hydroxyibogamine): a biologically active metabolite of the antiaddictive drug ibogaine. Ann N Y Acad Sci 2000 0.77
75 Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine. Psychopharmacology (Berl) 1996 0.77
76 Selective labeling and localization of the M4 (m4) muscarinic receptor subtype. Mol Pharmacol 1994 0.77
77 Multiple in vitro interactions with and differential in vivo regulation of muscarinic receptor subtypes by tetrahydroaminoacridine. J Pharmacol Exp Ther 1989 0.77
78 Pharmacological characterization of the vesamicol analogue (+)-[(125)I]MIBT in primate brain. Eur J Pharmacol 1997 0.77
79 Characterization and localization of galanin receptors in human entorhinal cortex. Regul Pept 1998 0.76
80 Galanin expression within the basal forebrain in Alzheimer's disease. Comments on therapeutic potential. Ann N Y Acad Sci 1998 0.76
81 Is ischemic cerebrovascular disease a risk factor for dementia in patients with Parkinson's disease? Acta Neurol Scand 2006 0.75
82 Are neuroadaptations in D3 dopamine receptors linked to the development of cocaine dependence? Mol Psychiatry 1997 0.75
83 Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes. J Med Chem 1998 0.75
84 A multicomponent learning model of drug abuse. Drug taking and craving may involve separate brain circuits underlying instrumental and classical conditioning, respectively. Ann N Y Acad Sci 1999 0.75
85 Nature-inspired indolyl-2-azabicyclo[2.2.2]oct-7-ene derivatives as promising agents for the attenuation of withdrawal symptoms: synthesis of 20-desethyl-20-hydroxymethyl-11-demethoxyibogaine. Nat Prod Res 2006 0.75
86 The effect of ischemic cerebrovascular disease on the clinical characteristics of Parkinson's disease. A post-mortem study. Eur J Neurol 2006 0.75
87 Identification and quantitation of ibogaine and an o-demethylated metabolite in brain and biological fluids using gas chromatography-mass spectrometry. J Anal Toxicol 1995 0.75
88 [3H]-(+)-pentazocine binding to sigma recognition sites in human cerebellum. Life Sci 1994 0.75
89 The effect of altered 5-hydroxytryptamine levels on beta-endorphin content in rat brain. Proc Soc Exp Biol Med 1986 0.75
90 Noribogaine generalization to the ibogaine stimulus: correlation with noribogaine concentration in rat brain. Neuropsychopharmacology 1999 0.75